Expert Interview
Discussing Moonlake's sonelokimab in hidradenitis suppurativa (HS) and the ongoing VELA trials
Ticker(s): MLTXInstitution: Mount Sinai Medical Center
- Specializes in medical dermatology, sexually transmitted diseases, genital dermatology,
and infectious diseases of the skin. - Interim Chairman of the Department of Dermatology at Mount Sinai
Beth Israel - Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai
- Director of the Adult Dermatology Consultation Service at Mount Sinai Beth Israel.
- Sees approximately 4 - 6 new Hidradenitis Suppurativa patients per month and familiar with Bimekizumab (Bimzelx). "It is a humanized anti-IL17AF monoclonal antibody made by UCB Pharmaceuticals."
How are you currently treating HS?
Added By: wilson_adminHave you started using Bimzelx?
Added By: wilson_adminWhat would you need to see in the VELA trial to justify use of sonelokimab over Bimzelx?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
